Apogee Therapeutics stock delisted from Nasdaq
Apogee Therapeutics, Inc. (APGE) is having its common stock removed from listing and registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934.
Rhea-AI Filing Summary
Apogee Therapeutics, Inc. (APGE) is having its common stock removed from listing and registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934. Nasdaq filed a Form 25, certifying it has complied with its own rules and SEC Rule 12d2-2 for striking the common stock from listing and withdrawing its registration on the exchange.
Positive
- None.
Negative
- None.
Key Terms
Form 25, Section 12(b), 17 CFR 240.12d2-2(b), 17 CFR 240.12d2-2(c)
4 terms
Form 25 regulatory
"FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION"
A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.
Section 12(b) regulatory
"registration under Section 12(b) of the Securities Exchange Act of 1934"
Section 12(b) of the U.S. Securities Exchange Act requires securities listed on a national stock exchange to be registered with the U.S. Securities and Exchange Commission (SEC) and to follow regular public reporting and disclosure rules. For investors, a 12(b) listing generally means more routine financial updates, regulatory oversight and easier buying and selling—like a storefront that must display its inventory and prices, making it simpler to inspect and trade the product.
17 CFR 240.12d2-2(b) regulatory
"Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied"
17 CFR 240.12d2-2(c) regulatory
"requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal"
FAQ
What does Apogee Therapeutics (APGE) disclose in this Form 25 filing?
The filing states that Nasdaq Stock Market LLC filed Form 25 to remove Apogee Therapeutics’ common stock from listing and registration under Section 12(b) of the Exchange Act, after certifying compliance with its own rules and SEC Rule 12d2-2.
Which Apogee Therapeutics (APGE) security is affected by this Form 25?
The Form 25 covers Apogee Therapeutics, Inc. common stock. The notice specifies “Common Stock” as the class of securities subject to removal from listing and registration on the Nasdaq Stock Market LLC.
Under what SEC rule is Apogee Therapeutics’ (APGE) common stock being removed from listing?
The removal is made under SEC Rule 12d2-2, cited as 17 CFR 240.12d2-2(b) and 17 CFR 240.12d2-2(c), which govern exchange-initiated striking of a listing and issuer-initiated voluntary withdrawal from listing and registration.
What law governs the Form 25 filed for Apogee Therapeutics (APGE)?
The Form 25 is filed under the Securities Exchange Act of 1934, specifically concerning removal from listing and/or registration under Section 12(b) for Apogee Therapeutics’ common stock on Nasdaq.
AI-generated analysis. How Rhea-AI works. Not financial advice.
